The growth of Viagra and its effect on the medicinal landscape presents a complex question for shareholders. While the early sales data were remarkable, the patent has expired, leading to a deluge of off-brand alternatives that are chipping away at revenue. In addition, the sector is facing issues related to demographic trends and changing healt… Read More